Developer docs
API playgroundTry for free, no card

Search company profiles

Concile

Full company profile

uuid000g4lc

Namestring
Concile
Legal namestring
concil GmbH
Websiteurl
concile.de
Company typeenum
Private
Founded yearint
2010
Descriptiontext

concil GmbH is a privately held, family-owned German medical diagnostics company headquartered in Freiburg im Breisgau that develops, produces, and distributes point-of-care (POC) rapid diagnostic tests and compatible measurement devices for physician practices in Germany. Founded around 2010, the company operates a mid-sized German Mittelstand with fourteen regional field sales teams covering all major territories and a Shopify-based e-commerce storefront for direct practice purchases. Its portfolio spans nine diagnostic categories — tumor diagnostics (CancerCheck®, ScheBo M2-PK, PSA/fPSA, HPV High Risk), hormone diagnostics (CrinoCheck® Vitamin D, TSH, Testosteron, LH-FSH, SHBG, AMH, Prolaktin), infection diagnostics (InfectCheck® CRP, SARS-CoV-2/RSV/FluA/FluB, Strep A, PCT, NeoPT), molecular STI testing (Pluslife NG/UU, TV/MG), cardiac diagnostics (MyoCheck® sPLA2-IIA, BodyCheck® HCY), gastrointestinal diagnostics (GastroPanel® Quick Test, ScheBo), diabetes diagnostics (BodyCheck® HbA1c), and sepsis diagnostics (SeptiLoop®), plus a sperm analysis system (SQA-iO) launched in 2025.

The underlying technology relies on lateral flow immunochromatographic assays and fluorescence immunoassays measured by proprietary readers (concile α1, Ω100, DUO, and GP Reader) that are RiliBÄK-compliant for German billing. Recent extensions into molecular diagnostics (Pluslife Mini Dock, launched November 2025) and digital urology (Streamcheck partnership, February 2026) signal a shift beyond purely consumable lateral flow products toward integrated hardware-software-and-molecular platforms. SeptiLoop, the company's flagship sepsis test, is CE-IVDR Class C certified and UKCA approved, representing the highest-risk in-vitro diagnostic classification in the portfolio.

The business model combines one-time hardware sales (readers at €5,870–€10,060+, SQA-iO bundles), recurring consumable test sales (typically packs of 20–25 tests), and — increasingly — subscription-style digital services bundled with hardware. Tests are billable to German private practice economics via the GOÄ fee schedule or as IGeL (individual health services), allowing practices to generate direct revenue from in-office testing; concile actively markets this practice-revenue angle through an online Wirtschaftlichkeitsrechner (profitability calculator). The company is ISO 13485:2016 certified and VDGH Code-compliant, with its own brand portfolio (CancerCheck, CrinoCheck, InfectCheck, GastroPanel, MyoCheck, BodyCheck, Pluslife, SeptiLoop) sitting alongside distributed partner products such as ScheBo assays. Management is led by Managing Director (Geschäftsführer) Michael Maier, and the company has no disclosed external funding rounds, acquisitions, or institutional investors.

Short descriptiontext

concil GmbH is a German, family-owned distributor and developer of point-of-care rapid diagnostic tests and proprietary readers serving urology, gynecology, internal medicine practices, and pharmacies across Germany, with a portfolio spanning tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFreiburg, Germany
HQ citystring
Freiburg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
point-of-care diagnostics, rapid diagnostic tests, in-vitro diagnostics, lateral flow assays, molecular diagnostics
Industry3 codes
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Wholesale-Medical, Dental & Hospital Equipment & Supplies5047
Product category
Point-of-Care In-Vitro Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Rapid Diagnostic Tests
TypeHardware Sales
Description

Sale of qualitative and quantitative rapid tests across multiple diagnostic categories including tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics. Tests are sold in packages (typically 20 or 25 tests per unit) through e-commerce and field sales. Revenue is one-time per transaction with recurring purchase patterns driven by practice volume.

concile.de
2Diagnostic Readers/Meters
TypeHardware Sales
Description

Sale of proprietary Point-of-Care measurement devices including concile® α1 Reader, concile® Ω100 Reader, concile® DUO Reader, Pluslife Mini Dock, and GP Reader. These readers are required to perform quantitative rapid tests, creating a hardware + consumables model.

concile.de
3GOÄ/IGeL Reimbursement
TypeTransaction Fee
Description

Tests are billable through GOÄ (Gebührenordnung für Ärzte) or as IGeL (Individuelle Gesundheitsleistungen). The company's profitability calculator demonstrates how practices can generate revenue through point-of-care testing, with each test having associated profit margins based on marker type and test volume.

concile.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
Pricing details5 tiers
1SeptiLoop® - 20 qualitative Lateral-Flow-Tests for sepsis diagnostics
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Price on request (request via contact form). CE-IVDR Class C certified sepsis test with 3-hour results.

concile.de
2SQA-iO Single - Sperm analysis system
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

List price: €5,870. Includes SQA-iO unit, visualization unit, docking station, QwikCheck Test Kit (50x), Liquefaction Kit (20x), Quality Control (3x).

concile.de
3SQA-iO Bundle - Complete sperm analysis system
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

List price: €10,060. Includes all components plus extended kit quantities for higher volume practices.

concile.de
4Streamcheck Portal - First year benefit
ModelSubscriptionBilling cadenceAnnual
Notes

Streamcheck Portal valued at €600 (incl. 7% VAT) offered free for first year as concile partner benefit. CME-certified webinars included.

concile.de
5Standard Shipping
ModelUnit PricingBilling cadencePay-as-you-go
Notes

€5.00 shipping for orders under €250. Free shipping for orders over €250. Ships via DPD or freight forwarder for pallet shipments.

concile.de
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1CancerCheck®
Description

Rapid tests for bladder, colorectal, and prostate cancer detection as well as HPV-associated tumor diagnostics

concile.de
+7 more records
Core offering1 text field

concile GmbH develops, manufactures, and distributes point-of-care rapid diagnostic tests and proprietary measurement readers for German medical practices. The portfolio spans nine diagnostic categories — tumor, hormone, cardiac, infection, gastrointestinal, diabetes, molecular (STI), sperm analysis, and sepsis diagnostics — using lateral flow immunochromatographic assays and nucleic acid testing. Tests are sold packaged in quantities of 20-25 alongside proprietary readers (concile α1, Ω100, DUO, GP Reader, Pluslife Mini Dock) that produce results in 10 to 35 minutes.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • SeptiLoop® detects sepsis within 1 hour of infection onset with results in 3 hours, with up to 3x higher accuracy than standard tests
+3 more records
Product overview1 text field

Concile is a German medical diagnostics company offering a comprehensive portfolio of point-of-care rapid tests and compatible measurement devices for physician practices, pharmacies, and hospitals. The product ecosystem consists of: (1) quantitative and qualitative rapid tests across diagnostic categories including tumor diagnostics (CancerCheck UBC Rapid, ScheBo M2-PK Quick, CancerCheck PSA/fPSA, CancerCheck HPV High Risk), hormone diagnostics (CrinoCheck Vitamin D, TSH, Testosteron, Prolaktin, LH-FSH, AMH, SHBG), infection diagnostics (InfectCheck CRP, SARS-CoV-2/RSV/FluA/FluB, Strep A, PCT, NeoPT, Pluslife NG/UU, TV/MG), cardiac diagnostics (MyoCheck sPLA2-IIA, BodyCheck HCY), gastrointestinal diagnostics (GastroPanel Quick Test, ScheBo tests), diabetes diagnostics (BodyCheck HbA1c), and sepsis diagnostics (SeptiLoop); (2) point-of-care readers (concile α1 Reader, Ω100 Reader, DUO Reader, GP Reader) that measure quantitative rapid tests; and (3) molecular diagnostic systems (Pluslife Mini Dock) for nucleic acid testing of sexually transmitted infections. All products are CE-certified and manufactured under ISO 13485 quality management. Tests can be billed through GOÄ (private) or IGeL (individual health service) systems.

Product and service2 records
1CancerCheck UBC Rapid
CategoryTumor diagnostics
Description

Quantitative immunochromatographic rapid test for bladder cancer diagnostics measuring urinary cytokeratin 8/18 fragments (UBC) in 5-300 µg/l range with results in 10 minutes. For urology practices.

2CancerCheck UBC Rapid VISUAL
CategoryTumor diagnostics
Description

Qualitative lateral flow rapid test for bladder cancer screening and monitoring via visual detection of urinary cytokeratin 8/18 fragments; no reader required.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-02
Description

Strategic partnership adding Streamcheck's digital urological diagnostics platform to concile's portfolio. Streamcheck enables uroflow and biomarker measurements both in practice and as structured home-based test series. The system includes a precise handheld device combined with a digital practice platform that automatically captures, evaluates, and presents measurement data for physician assessment. Medical device Class I (MDR). Concile partners receive Streamcheck Portal (€600 value) free for first year.

2Doctolib
Strategic tierMinorTypeGTM or Marketing Partner
Description

European health-tech company with platform for doctor appointments, patient communication, and video consultations. Partnership likely enables appointment booking integration for concile's customers.

concile.de
3HonorarExpert GmbH
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

German provider of billing and compensation consulting for doctors. Supports practices with analysis, optimization, and ensuring correct billing according to GOÄ and EBM standards. Helps practices maximize revenue from point-of-care diagnostics.

concile.de
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

UK-listed point-of-care diagnostics company with rapid test and reader products (QuikRead, Hemo Control) serving physician offices and decentralized care settings in Europe — a comparable mid-sized European POCT specialist.

2Boditech Med Inc.
TypeDirect peer
Description

Korean POCT manufacturer with the AFIAS and ichroma reader platforms offering quantitative rapid tests across infection, cardiac, tumor, and hormone markers, distributed globally including Europe — directly comparable in product architecture (reader + consumables) and clinical menu.

TypeBroad incumbent
Description

Global French-listed microbiology and IVD company with strong sepsis diagnostics franchise (BACT/ALERT, VIDAS) overlapping with concile's SeptiLoop® sepsis POC focus, and a broader infectious disease menu relevant to practice-level customers.

TypeBroad incumbent
Description

Global clinical diagnostics and POCT company offering rapid tests and readers (ACON, OSOM brands) across infectious disease, cardiac, and women's health — overlapping menu categories with concile but with broader portfolio and global reach.

TypeDirect peer
Description

German POCT rapid test manufacturer offering a broad lateral flow and reader portfolio (CRP, HbA1c, hormones, infectious disease) sold through a similar direct-to-practice distribution model across German-speaking markets. Most direct structural peer to concile in size, geography, and channel.

TypeRegional player
Description

Italian in-vitro diagnostics manufacturer producing rapid tests and clinical chemistry reagents for European hospital and practice laboratories — comparable mid-sized European specialty IVD company with overlapping clinical menu but primarily Southern European distribution.

7MöLab GmbH
TypeDirect peer
Description

German specialist distributor and developer of point-of-care rapid diagnostics for medical practices, offering a comparable range of infectious disease, cardiac, and hormone rapid tests with practice-facing field sales in the German market.

TypeBroad incumbent
Description

Northern Ireland-based global diagnostics manufacturer with extensive POCT and laboratory diagnostics portfolio. Listed as a concile technology/integration partner, indicating product overlap in IVD reagents and analyzers relevant to comparable practice settings.

TypeBroad incumbent
Description

Merged US diagnostics major combining Quidel's rapid immunoassay portfolio (Sofia, Triage) with Ortho's clinical chemistry and immunoassay systems, serving physician offices and hospitals globally — a broader incumbent operating in overlapping POC categories.

10Abbott Point of Care
TypeBroad incumbent
Description

Global POC diagnostics leader with the i-STAT system serving physician offices, urgent care, and hospital point-of-care across cardiac, infection, and metabolic markers — a major incumbent competing for the same practice-level rapid testing budgets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Concile

Point-of-Care In-Vitro Diagnosticsconcile.de

concil GmbH is a German, family-owned distributor and developer of point-of-care rapid diagnostic tests and proprietary readers serving urology, gynecology, internal medicine practices, and pharmacies across Germany, with a portfolio spanning tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics.

What Concile does

concil GmbH is a privately held, family-owned German medical diagnostics company headquartered in Freiburg im Breisgau that develops, produces, and distributes point-of-care (POC) rapid diagnostic tests and compatible measurement devices for physician practices in Germany. Founded around 2010, the company operates a mid-sized German Mittelstand with fourteen regional field sales teams covering all major territories and a Shopify-based e-commerce storefront for direct practice purchases. Its portfolio spans nine diagnostic categories — tumor diagnostics (CancerCheck®, ScheBo M2-PK, PSA/fPSA, HPV High Risk), hormone diagnostics (CrinoCheck® Vitamin D, TSH, Testosteron, LH-FSH, SHBG, AMH, Prolaktin), infection diagnostics (InfectCheck® CRP, SARS-CoV-2/RSV/FluA/FluB, Strep A, PCT, NeoPT), molecular STI testing (Pluslife NG/UU, TV/MG), cardiac diagnostics (MyoCheck® sPLA2-IIA, BodyCheck® HCY), gastrointestinal diagnostics (GastroPanel® Quick Test, ScheBo), diabetes diagnostics (BodyCheck® HbA1c), and sepsis diagnostics (SeptiLoop®), plus a sperm analysis system (SQA-iO) launched in 2025.

The underlying technology relies on lateral flow immunochromatographic assays and fluorescence immunoassays measured by proprietary readers (concile α1, Ω100, DUO, and GP Reader) that are RiliBÄK-compliant for German billing. Recent extensions into molecular diagnostics (Pluslife Mini Dock, launched November 2025) and digital urology (Streamcheck partnership, February 2026) signal a shift beyond purely consumable lateral flow products toward integrated hardware-software-and-molecular platforms. SeptiLoop, the company's flagship sepsis test, is CE-IVDR Class C certified and UKCA approved, representing the highest-risk in-vitro diagnostic classification in the portfolio.

The business model combines one-time hardware sales (readers at €5,870–€10,060+, SQA-iO bundles), recurring consumable test sales (typically packs of 20–25 tests), and — increasingly — subscription-style digital services bundled with hardware. Tests are billable to German private practice economics via the GOÄ fee schedule or as IGeL (individual health services), allowing practices to generate direct revenue from in-office testing; concile actively markets this practice-revenue angle through an online Wirtschaftlichkeitsrechner (profitability calculator). The company is ISO 13485:2016 certified and VDGH Code-compliant, with its own brand portfolio (CancerCheck, CrinoCheck, InfectCheck, GastroPanel, MyoCheck, BodyCheck, Pluslife, SeptiLoop) sitting alongside distributed partner products such as ScheBo assays. Management is led by Managing Director (Geschäftsführer) Michael Maier, and the company has no disclosed external funding rounds, acquisitions, or institutional investors.

Concile firmographics

Firmographics
Name
Concile
Legal name
concil GmbH
Website
https://concile.de
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
concil GmbH is a German, family-owned distributor and developer of point-of-care rapid diagnostic tests and proprietary readers serving urology, gynecology, internal medicine practices, and pharmacies across Germany, with a portfolio spanning tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics.
Ownership category
akta.pro rank

Concile industry classification

Industry
Product category
Point-of-Care In-Vitro Diagnostics
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
akta.pro industry
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics

Keywords

  • Point-of-care diagnostics
  • Rapid diagnostic tests
  • In-vitro diagnostics
  • Lateral flow assays
  • Molecular diagnostics

Where Concile is headquartered

Location

Headquarters

HQ city
Freiburg
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Concile business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Rapid Diagnostic Tests: Sale of qualitative and quantitative rapid tests across multiple diagnostic categories including tumor, hormone, cardiac, infection, gastrointestinal, diabetes, and molecular diagnostics. Tests are sold in packages (typically 20 or 25 tests per unit) through e-commerce and field sales. Revenue is one-time per transaction with recurring purchase patterns driven by practice volume.
  2. Diagnostic Readers/Meters: Sale of proprietary Point-of-Care measurement devices including concile® α1 Reader, concile® Ω100 Reader, concile® DUO Reader, Pluslife Mini Dock, and GP Reader. These readers are required to perform quantitative rapid tests, creating a hardware + consumables model.
  3. GOÄ/IGeL Reimbursement: Tests are billable through GOÄ (Gebührenordnung für Ärzte) or as IGeL (Individuelle Gesundheitsleistungen). The company's profitability calculator demonstrates how practices can generate revenue through point-of-care testing, with each test having associated profit margins based on marker type and test volume.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goSeptiLoop® - 20 qualitative Lateral-Flow-Tests for sepsis diagnostics
One time/ perpetual licensePay-as-you-goSQA-iO Single - Sperm analysis system
One time/ perpetual licensePay-as-you-goSQA-iO Bundle - Complete sperm analysis system
SubscriptionAnnualStreamcheck Portal - First year benefit
Unit PricingPay-as-you-goStandard Shipping

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Concile product offering

Product offering

Core offering

concile GmbH develops, manufactures, and distributes point-of-care rapid diagnostic tests and proprietary measurement readers for German medical practices. The portfolio spans nine diagnostic categories — tumor, hormone, cardiac, infection, gastrointestinal, diabetes, molecular (STI), sperm analysis, and sepsis diagnostics — using lateral flow immunochromatographic assays and nucleic acid testing. Tests are sold packaged in quantities of 20-25 alongside proprietary readers (concile α1, Ω100, DUO, GP Reader, Pluslife Mini Dock) that produce results in 10 to 35 minutes.

Product overview

Concile is a German medical diagnostics company offering a comprehensive portfolio of point-of-care rapid tests and compatible measurement devices for physician practices, pharmacies, and hospitals. The product ecosystem consists of: (1) quantitative and qualitative rapid tests across diagnostic categories including tumor diagnostics (CancerCheck UBC Rapid, ScheBo M2-PK Quick, CancerCheck PSA/fPSA, CancerCheck HPV High Risk), hormone diagnostics (CrinoCheck Vitamin D, TSH, Testosteron, Prolaktin, LH-FSH, AMH, SHBG), infection diagnostics (InfectCheck CRP, SARS-CoV-2/RSV/FluA/FluB, Strep A, PCT, NeoPT, Pluslife NG/UU, TV/MG), cardiac diagnostics (MyoCheck sPLA2-IIA, BodyCheck HCY), gastrointestinal diagnostics (GastroPanel Quick Test, ScheBo tests), diabetes diagnostics (BodyCheck HbA1c), and sepsis diagnostics (SeptiLoop); (2) point-of-care readers (concile α1 Reader, Ω100 Reader, DUO Reader, GP Reader) that measure quantitative rapid tests; and (3) molecular diagnostic systems (Pluslife Mini Dock) for nucleic acid testing of sexually transmitted infections. All products are CE-certified and manufactured under ISO 13485 quality management. Tests can be billed through GOÄ (private) or IGeL (individual health service) systems.

Differentiator

Problem solved

Functional benefit

Brands

  • CancerCheck®: Rapid tests for bladder, colorectal, and prostate cancer detection as well as HPV-associated tumor diagnostics
  • CrinoCheck®
  • InfectCheck®
  • concile® Readers (α1, Ω100, DUO)
  • MyoCheck® / BodyCheck®
  • Pluslife Mini Dock
  • GastroPanel®
  • SeptiLoop®

Products and services

  • CancerCheck UBC Rapid Quantitative immunochromatographic rapid test for bladder cancer diagnostics measuring urinary cytokeratin 8/18 fragments (UBC) in 5-300 µg/l range with results in 10 minutes. For urology practices.
  • CancerCheck UBC Rapid VISUAL Qualitative lateral flow rapid test for bladder cancer screening and monitoring via visual detection of urinary cytokeratin 8/18 fragments; no reader required.

Quantifiable outcome

  • SeptiLoop® detects sepsis within 1 hour of infection onset with results in 3 hours, with up to 3x higher accuracy than standard tests
  • +3 more outcomes

Companies that use Concile

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Concile technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Concile partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • Streamcheck GmbHcoreStrategic or Co-development Partner · 2 February 2026Strategic partnership adding Streamcheck's digital urological diagnostics platform to concile's portfolio. Streamcheck enables uroflow and biomarker measurements both in practice and as structured home-based test series. The system includes a precise handheld device combined with a digital practice platform that automatically captures, evaluates, and presents measurement data for physician assessment. Medical device Class I (MDR). Concile partners receive Streamcheck Portal (€600 value) free for first year.
  • DoctolibminorGTM or Marketing PartnerEuropean health-tech company with platform for doctor appointments, patient communication, and video consultations. Partnership likely enables appointment booking integration for concile's customers.
  • HonorarExpert GmbHminorImplementation/ SI/ Consulting PartnerGerman provider of billing and compensation consulting for doctors. Supports practices with analysis, optimization, and ensuring correct billing according to GOÄ and EBM standards. Helps practices maximize revenue from point-of-care diagnostics.

Scale indicators3 records

Recent moves5 records

Expansion highlights6 records

Concile competitors and assessment

Company assessment

Direct peers

  • EKF Diagnostics Holdings plc: UK-listed point-of-care diagnostics company with rapid test and reader products (QuikRead, Hemo Control) serving physician offices and decentralized care settings in Europe — a comparable mid-sized European POCT specialist.
  • Boditech Med Inc. Korean POCT manufacturer with the AFIAS and ichroma reader platforms offering quantitative rapid tests across infection, cardiac, tumor, and hormone markers, distributed globally including Europe — directly comparable in product architecture (reader + consumables) and clinical menu.
  • nal von minden GmbH: German POCT rapid test manufacturer offering a broad lateral flow and reader portfolio (CRP, HbA1c, hormones, infectious disease) sold through a similar direct-to-practice distribution model across German-speaking markets. Most direct structural peer to concile in size, geography, and channel.
  • MöLab GmbH: German specialist distributor and developer of point-of-care rapid diagnostics for medical practices, offering a comparable range of infectious disease, cardiac, and hormone rapid tests with practice-facing field sales in the German market.

Broad incumbents

  • bioMérieux SA: Global French-listed microbiology and IVD company with strong sepsis diagnostics franchise (BACT/ALERT, VIDAS) overlapping with concile's SeptiLoop® sepsis POC focus, and a broader infectious disease menu relevant to practice-level customers.
  • Sekisui Diagnostics: Global clinical diagnostics and POCT company offering rapid tests and readers (ACON, OSOM brands) across infectious disease, cardiac, and women's health — overlapping menu categories with concile but with broader portfolio and global reach.
  • Randox Laboratories Ltd. Northern Ireland-based global diagnostics manufacturer with extensive POCT and laboratory diagnostics portfolio. Listed as a concile technology/integration partner, indicating product overlap in IVD reagents and analyzers relevant to comparable practice settings.
  • QuidelOrtho Corporation: Merged US diagnostics major combining Quidel's rapid immunoassay portfolio (Sofia, Triage) with Ortho's clinical chemistry and immunoassay systems, serving physician offices and hospitals globally — a broader incumbent operating in overlapping POC categories.
  • Abbott Point of Care: Global POC diagnostics leader with the i-STAT system serving physician offices, urgent care, and hospital point-of-care across cardiac, infection, and metabolic markers — a major incumbent competing for the same practice-level rapid testing budgets.

Regional players

  • Sentinel Diagnostics: Italian in-vitro diagnostics manufacturer producing rapid tests and clinical chemistry reagents for European hospital and practice laboratories — comparable mid-sized European specialty IVD company with overlapping clinical menu but primarily Southern European distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Concile social profiles

Digital presence

Concile compliance and trust

Trust signal

Compliance3 records

Concile financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Concile leadership team

Management profile

Number of profiles

Profiles1 record

Concile funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Concile M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Concile

What does Concile do?

concile GmbH develops, manufactures, and distributes point-of-care rapid diagnostic tests and proprietary measurement readers for German medical practices. The portfolio spans nine diagnostic categories — tumor, hormone, cardiac, infection, gastrointestinal, diabetes, molecular (STI), sperm analysis, and sepsis diagnostics — using lateral flow immunochromatographic assays and nucleic acid testing. Tests are sold packaged in quantities of 20-25 alongside proprietary readers (concile α1, Ω100, DUO, GP Reader, Pluslife Mini Dock) that produce results in 10 to 35 minutes.

Is Concile a public or private company?

Concile is a private company. It is classified as family owned and is currently operating.

When was Concile founded?

Concile was founded in 2010. It employs 11 to 50 people.

Where is Concile based?

Concile is headquartered in Freiburg, Germany, in the Europe region.

How does Concile make money?

Three revenue lines are on record. Rapid Diagnostic Tests are the primary driver. The others are diagnostic Readers/Meters and GOÄ/IGeL Reimbursement.

Who are Concile's main competitors?

Direct peers on record are EKF Diagnostics Holdings plc, Boditech Med Inc., nal von minden GmbH and MöLab GmbH. Broad incumbents are bioMérieux SA, Sekisui Diagnostics, Randox Laboratories Ltd., QuidelOrtho Corporation and Abbott Point of Care. Sentinel Diagnostics is listed as a regional player.

Does Concile have an API?

No public API is recorded for Concile.

What industry is Concile in?

Concile's product category is Point-of-Care In-Vitro Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection). Its NAICS code is 3391 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals